Skip to main content

Table 3 Comparison of QoL scores between regimens based on nevirapine or efavirenz over the follow-up period using GEE

From: Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine or efavirenz in Uganda: a prospective non-randomized study

QoL summary score β coefficient (95 % CI) β coefficient (95 % CI)
OR (95 % CI) OR (95 % CI)
unadjusted Adjusted
PHS   
CD4 count <100 cells/μl   
NVP Ref Ref
EFV −1.61(−2.82 to −0.40) −1.61 (−2.74 to −0.49)a
P = 0.11d
CD4 count 101–250 cells/μl   
NVP Ref Ref
EFV 0.17 (−0.70 to 1.05) 0.82 (0.22 to 1.43)a
P = 0.76d
CD4 count >250 cells/μl   
NVP Ref Ref
EFV 0.97 (−0.35 to 2.30) −1.33 (−5.66 to 3.00)a
P = 0.90d
MHS   
CD4 count <100 cells/μl   
NVP Ref Ref
EFV −0.18 (−1.18 to 0.82) −0.39 (−1.40 to 0.62)b
P = 0.91d
CD4 count 101–250 cells/μl   
NVP Ref  
EFV −0.09 (−0.93 to 0.75) 0.16 (−0.66 to 0.98)b
P = 0.78d
CD4 count >250 cells/μl   
NVP Ref Ref
EFV −0.84 (−2.09 to 0.42) −0.75 (−2.01 to 0.51)b
P = 0.65d
GPGI   
CD4 count <100 cells/μlEFV versus NVP   
  −0.59 (0.31 to 1.13) 0.51 (0.25 to1.04)c
P = 0.54d
CD4 count 101–250 cells/μl   
EFV versus NVP 0.85 (0.54 to 1.33) 0.98 (0.60 to 1.56)c
P = 0.08d
CD4 count >250 cells/μl   
EFV versus NVP 1.30 (0.66 to 2.56) 1.39 (0.66 to 2.90)c
P = 0.08d
  1. aadjusted for age, study visit, diagnosis of depression, income per month, WHO stage, education level and opportunistic infection
  2. badjusted for sex, age, study visit, WHO stage, marital status, social support and level of education
  3. cadjusted for sex, age, study visit, WHO stage, education level, income per month, depression, employment status, alcohol use, social support and opportunistic infection
  4. dP value for interaction term (time*ART regimen)
\